## NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

## **Review Proposal Project**

# NICE Technology Appraisal No. 236; Ticagrelor for the treatment of acute coronary syndromes

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
Manufactura valance and	appeal)
Manufacturers/sponsors	General
AstraZeneca (ticagrelor)	Allied Health Professionals Federation
Dationt/source suscess	Board of Community Health Councils in
Patient/carer groups	Wales
Action Heart	British National Formulary
Afiya Trust	Care Quality Commission
Black Health Agency	Commissioning Support Appraisals
Blood Pressure UK	Service
British Cardiac Patients Association	Department of Health, Social Services
Cardiac Risk in the Young	and Public Safety for Northern Ireland
Coronary Prevention Group	Healthcare Improvement Scotland
Equalities National Council	Medicines and Healthcare Products
Heart Care Partnership	Regulatory Agency
HEART UK	<ul> <li>National Association of Primary Care</li> </ul>
Independent Age	<ul> <li>National Pharmacy Association</li> </ul>
Muslim Council of Britain	NHS Alliance
Muslim Health Network	<ul> <li>NHS Commercial Medicines Unit</li> </ul>
Network of Sikh Organisations	NHS Confederation
South Asian Health Foundation	<ul> <li>Public Health Wales NHS Trust</li> </ul>
Specialised Healthcare Alliance	<ul> <li>Scottish Medicines Consortium</li> </ul>
The Somerville Foundation (formerly	
known as Grown Up Congenital Heart	Comparator manufacturers
Patients Association)	Actavis UK (clopidogrel)
,	Arrow Generics (clopidogrel)
Professional groups	Aspire Pharma (clopidogrel)
British Association for Nursing in	Beacon Pharmaceuticals (clopidogrel)
Cardiovascular Care	Daiichi Sankyo (prasugrel)
British Association for Services to the	Dexcel-Pharma (clopidogrel)
Elderly	Dr Reddy's Laboratories (clopidogrel)
British Atherosclerosis Society	Lilly UK (prasugrel)
British Cardiovascular Intervention	Sandoz (clopidogrel)
Society	Sanofi (clopidogrel)
British Cardiovascular Society	Teva UK (clopidogrel)
British Geriatrics Society	Wockhardt UK (clopidogrel)
British Heart Foundation	(Sispinagion)
British Nuclear Cardiology Society	Relevant research groups
British Society For Heart Failure	Antithrombotic Trialists' (ATT)
British Society of Cardiovascular	Collaboration

National Institute for Health and Clinical Excellence

NICE Technology Appraisal No. 236; Ticagrelor for the treatment of acute coronary syndromes Issue date: March 2013

#### **Imaging**

- College of Emergency Medicine
- National Heart Forum
- Primary Care Cardiovascular Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiological Science and Technology
- United Kingdom Clinical Pharmacy Association
- Vascular Society of Great Britain and Ireland

#### Others

- Cambridgeshire and Peterborough PCT Cluster
- Department of Health
- Hertfordshire PCT Cluster
- Welsh Government

- British Society for Cardiovascular Research [BCS affiliated]
- Cardiac and Cardiology Research Dept, Barts
- Central Cardiac Audit Database
- Cochrane Heart Group
- Cochrane Hypertension Group
- Cochrane Peripheral Vascular Diseases Group
- Cochrane Stroke Group
- CORDA
- European Council for Cardiovascular Research
- MRC Clinical Trials Unit
- National Heart Research Fund
- National Institute for Health Research
- Research Institute for the Care of Older People
- Wellcome Trust

#### **Assessment Group**

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

#### **Associated Guideline Groups**

National Clinical Guidelines Centre

#### Associated Public Health Groups

None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

## Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.